Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company�) is pleased to announce that it has engaged Guy Ricciardulli for services related to claims for damages, injury or loss out of patent infringement. �We are pleased to have Guy and his exceptional team working with us on protecting our intellectual property estate,� stated John Stanton, Nanobac�s Chairman and CEO. �We are at a true turning point at Nanobac with our science, our products and our partnerships, and we need to protect our intellectual property estate.� Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com. Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
Nanobac Pharmaceuticals (CE) (USOTC:NNBP)
éŽåŽ» 株価ãƒãƒ£ãƒ¼ãƒˆ
ã‹ã‚‰ 11 2024 ã¾ã§ 12 2024 Nanobac Pharmaceuticals (CE)ã®ãƒãƒ£ãƒ¼ãƒˆã‚’ã‚‚ã£ã¨è¦‹ã‚‹ã«ã¯ã“ã¡ã‚‰ã‚’クリック
Nanobac Pharmaceuticals (CE) (USOTC:NNBP)
éŽåŽ» 株価ãƒãƒ£ãƒ¼ãƒˆ
ã‹ã‚‰ 12 2023 ã¾ã§ 12 2024 Nanobac Pharmaceuticals (CE)ã®ãƒãƒ£ãƒ¼ãƒˆã‚’ã‚‚ã£ã¨è¦‹ã‚‹ã«ã¯ã“ã¡ã‚‰ã‚’クリック